What could you do if your data was working for you and not against you? With Bloomberg delivering

enterprise data directly to your systems, you get easy access to the details you want, optimized for

higher level analysis, and financial data experts committed to helping you maximize your every move.

Our data is made for more, so you can show the world what you're made of. Visit Bloomberg.com slash enterprise data to learn more.

Welcome to Prognosis. I'm Laura Carlson. It's day 184 since coronavirus was declared a global pandemic.

Today's main story, scientists are learning more about how long the virus lingers in all kinds of places,

from face masks to concrete sidewalks. They're also testing what weather conditions it likes best.

Their findings could indicate we're in for a frightening winter. But first, here's what

happened in virus news today.

The newest COVID-19 vaccine candidate to start human testing is the first where volunteers won't get a painful injection. Instead, they'll receive a spray through the nose.

This week, China approved Phase 1 human testing for a nasal spray vaccine,

developed by researchers at Jhemen University, Hong Kong University,

and vaccine maker Beijing-Wanthai Biological Pharmacy Enterprise.

Intranasal spray is recommended for children, as well as adults, who want to avoid the more common needle injection.

Scientists around the world are working on sprays as an alternative to muscle jabs for all sorts of vaccines.

In the UK, coronavirus is spreading exponentially again for the first time in months.

It's prompting government representatives to urge the public to limit social activities.

The government believes the so-called R-rate,

the number of people that one infected person will pass the virus onto,

is somewhere between 1 and 1.2.

It was last above 1 in March.

A separate study by Imperial College found the virus is now doubling every seven to eight days.

...